AdjuCor GmbH
- Industry
- Medical Devices
- Founded Year
- 2012
- Headquarters
- Munich, Germany
- Employee Count
- 34
Key People
- Prof. Dr. Stephen Wildhirt - Co-Founder, Chief Executive and Medical Officer, Managing Director
- Dr. Andreas Maier - Chief Technology and Production Officer
- Dr. Johannes Clauss - Co-Chief Technology Officer & Chief Operation Officer
- Dr. M. Hamman de Vaal - Senior Commercial and Clinical Advisor
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical technology and device development.
Prof. Dr. Stephen Wildhirt, the Co-Founder and CEO, is a seasoned cardiac surgeon with over 2,000 open-heart procedures. Dr. Andreas Maier and Dr. Johannes Clauss bring expertise in medical device development and production, enhancing the company's technical capabilities.
- Clinical Need
-
Aspect: Very Strong
Summary: AdjuCor addresses a critical need in advanced heart failure treatment with its innovative reBEAT system.
The reBEAT device provides biventricular mechanical circulatory support without direct blood contact, potentially reducing complications associated with traditional devices. This innovation could significantly improve patient outcomes in advanced heart failure cases.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for cardiac assist devices is competitive, but AdjuCor's unique approach differentiates it.
The cardiac assist device market includes several established players. However, AdjuCor's reBEAT system's non-blood-contacting design and biventricular support set it apart, potentially offering a competitive edge.
- Technical Challenge
-
Aspect: Complex
Summary: Developing a non-blood-contacting, biventricular assist device presents significant technical challenges.
Creating a device that provides effective mechanical support without contacting blood requires advanced engineering and rigorous testing to ensure safety and efficacy, potentially leading to extended development periods.
- Patent
-
Aspect: Very Strong
Summary: AdjuCor holds robust patents protecting its innovative technology.
The company's patents cover the unique aspects of the reBEAT system, including its non-blood-contacting design and biventricular support, providing a competitive advantage and potential barriers to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: AdjuCor has secured substantial funding to support its development and commercialization efforts.
With over 40 million raised, including a 29 million Series B round led by MitrAssist Holdings Limited and a 2.5 million grant from the European Innovation Council, AdjuCor is well-positioned to advance its product development and market entry plans.
- Regulatory
-
Aspect: Running FIH
Summary: AdjuCor has initiated first-in-human clinical trials for the reBEAT system.
The successful implantation of the reBEAT device in five patients during first-in-human trials indicates progress toward regulatory approval, though further studies are required to demonstrate safety and efficacy comprehensively.
Opportunity Rollup
- Odds of Success
- 3.9
- Peak Market Share
- 4.85
- Segment CAGR
- 5.8%
- Market Segment
- Cardiac Assist Devices
- Market Sub Segment
- Biventricular Mechanical Circulatory Support
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.40 |
| 5 | 4.85 |
Key Takeaway
AdjuCor's innovative reBEAT system addresses a critical need in advanced heart failure treatment, supported by a strong team and substantial funding, positioning the company for potential success in a competitive market.